

Jean-Baptiste Bachet

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9258144/jean-baptiste-bachet-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

12,911
citations

37
h-index

113
g-index

129
ext. papers

15,218
ext. citations

5.8
avg, IF

5.44
L-index

#	Paper	IF	Citations
116	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022 , 101880	2.4	
115	Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.. <i>World Journal of Surgical Oncology</i> , 2022 , 20, 131	3.4	0
114	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.. <i>European Journal of Cancer</i> , 2022 , 168, 99-107	7.5	0
113	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021 , 124, 1941-1948	8.7	5
112	Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2021 , 148, 171-180	7.5	2
111	Identification of pancreatic adenocarcinoma molecular subtypes on histology slides using deep learning models.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4141-4141	2.2	1
110	Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3575-3575	2.2	
109	Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101431	2.4	3
108	Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101541	2.4	2
107	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3242-3250	2.2	9
106	Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. <i>Clinical Cancer Research</i> , 2021 , 27, 6491-6499	12.9	1
105	Chemotherapy of metastatic colon cancer in France: A population-based study. <i>Digestive and Liver Disease</i> , 2021 , 53, 1334-1342	3.3	0
104	Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020 , 32, 356-363	4.2	5
103	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , 2020 , 5, e000698	6	7
102	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5208-5216	12.9	12
101	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de CancÉrologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). <i>European Journal of Cancer</i> , 2020 , 136, 25-34	7.5	3
100	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020 , 122, 957-962	8.7	2

99	Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. <i>Cancers</i> , 2020 , 12,	6.6	10
98	Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in patients with advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4617-4617	2.2	
97	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102028	14.4	5
96	YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence. <i>Digestive and Liver Disease</i> , 2020 , 52, 214-220	3.3	1
95	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020 , 124, 91-101	7.5	40
94	Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 824-833	4	9
93	Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer. <i>European Radiology</i> , 2019 , 29, 3871-3880	8	6
92	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019 , 115, 97-106	7.5	15
91	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019 , 43, 663-668	2.4	9
90	Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first-line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. <i>International Journal of Oncology</i> , 2019 , 54, 1433-1445	4.4	5
89	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
88	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , 2019 , 8, 5070-5080	4.8	8
87	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019 , 11,	6.6	11
86	Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3575-3575	3.2	1
85	Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4136-4136	2.2	2
84	Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2019 , 9, 16971	4.9	25
83	hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. <i>Cancers</i> , 2019 , 11,	6.6	11
82	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 331-335	3.6	18

81	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019 , 145, 576-585	7.5	10
80	Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. <i>Surgical Oncology</i> , 2019 , 28, 121-127	2.5	6
79	LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. <i>Cancer Research</i> , 2018 , 78, 909-921	10.1	51
78	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). <i>BMC Cancer</i> , 2018 , 18, 762	4.8	53
77	Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4107-4107	2.2	5
76	Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study. <i>Digestive and Liver Disease</i> , 2018 , 50, 285-290	3.3	6
75	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. <i>Gastroenterology</i> , 2018 , 155, 1999-2013.e3	13.3	189
74	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2395-2406	59.2	1047
73	FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. <i>European Journal of Cancer</i> , 2018 , 104, 108-116	7.5	13
72	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). <i>Digestive and Liver Disease</i> , 2018 , 50, 1257-1271	3.3	65
71	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 337-346	18.8	20
70	CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. <i>European Radiology</i> , 2017 , 27, 3104-3116	8	86
69	Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. <i>Clinical Cancer Research</i> , 2017 , 23, 116-123	12.9	155
68	Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction?. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 537-544	4.7	17
67	PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. <i>Cellular and Molecular Life Sciences</i> , 2017 , 74, 4231-4243	10.3	14
66	Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017 , 74, 98-108	7.5	28
65	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3520-3520	2.2	2
64	Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3563-3563	2.2	

63	Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15127- e15127 ²² ₁₂₇ ¹		
62	Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). <i>Annals of Oncology</i> , 2016 , 27, 121-7	10.3	55
61	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016 , 48, 1498-1502	3.3	4
60	Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Management. <i>Pancreas</i> , 2016 , 45, e50-2	2.6	2
59	Current standards and new innovative approaches for treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2016 , 57, 10-22	7.5	97
58	Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. <i>Journal of Clinical Investigation</i> , 2016 , 126, 4140-4156	15.9	127
57	Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution. <i>Oncotarget</i> , 2016 , 7, 32100-12	3.3	40
56	Reply to the comment on Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort <i>British Journal of Cancer</i> , 2016 , 114, e9	8.7	3
55	Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. <i>Clinical Chemistry</i> , 2016 , 62, 1492-1503	5.5	54
54	PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. <i>Cancer Medicine</i> , 2016 , 5, 676-83	4.8	37
53	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. <i>Bulletin Du Cancer</i> , 2015 , 102, 324-31	2.4	38
52	Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 1215-24	12.9	59
51	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015 , 113, 989-95	8.7	121
50	Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. <i>Annals of Surgical Oncology</i> , 2015 , 22 Suppl 3, S1196-205	3.1	55
49	Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. <i>Histopathology</i> , 2015 , 66, 457-62	7.3	30
48	High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. <i>Histopathology</i> , 2015 , 67, 664-76	7.3	19
47	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. <i>BMC Cancer</i> , 2015 , 15, 653	4.8	8
46	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2015 , 44, 1141-7	2.6	48

45	Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. <i>Cancer</i> , 2015 , 121, 3290-7	6.4	77
44	FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. <i>Annals of Surgical Oncology</i> , 2015 , 22, 295-301	3.1	119
43	New challenges in perioperative management of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2281-93	5.6	47
42	Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3338-47	12.9	77
41	Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in , and in Patients with Lymph Node-Positive Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 346-353	1	6
40	Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2014 , 6, 156-69	3.4	32
39	Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors. <i>Molecular Cancer</i> , 2014 , 13, 246	42.1	10
38	Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 419-29	4.6	13
37	Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases. <i>Surgery</i> , 2013 , 154, 528-35	3.6	18
36	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013 , 49, 2531-41	7.5	29
35	Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. <i>Annals of Oncology</i> , 2013 , 24, 412-419	10.3	67
34	Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT. <i>Molecular Oncology</i> , 2013 , 7, 323-33	7.9	9
33	S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2013 , 49, 2643-53	7.5	23
32	Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. <i>Annals of Oncology</i> , 2013 , 24, 2057-61	10.3	139
31	Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. <i>PLoS ONE</i> , 2013 , 8, e61103	3.7	8
30	Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. <i>Gastroenterology</i> , 2012 , 143, 664-674.e6	13.3	184
29	Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. <i>Supportive Care in Cancer</i> , 2012 , 20, 909-21	3.9	39
28	Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. <i>Supportive Care in Cancer</i> , 2012 , 20, 1395-404	3.9	25

27	Salvage colectomy for endoscopically removed malignant colon polyps: is it possible to determine the optimal number of lymph nodes that need to be harvested?. <i>Colorectal Disease</i> , 2012 , 14, 79-86	2.1	13
26	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. <i>Annals of Oncology</i> , 2012 , 23, 570-576	10.3	54
25	Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2012 , 23, 2327-2335	10.3	56
24	Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3378-3386	2.2	251
23	Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. <i>Oncologist</i> , 2012 , 17, 555-68	5.7	34
22	Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 1430-7	2.2	44
21	Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 364-74	2.4	12
20	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1817-25	59.2	4650
19	From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. <i>Seminars in Oncology</i> , 2011 , 38, 521-32	5.5	37
18	Treatment of pancreatic cancer: what can we really predict today?. <i>Cancers</i> , 2011 , 3, 675-99	6.6	5
17	Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors. <i>The Application of Clinical Genetics</i> , 2010 , 3, 85-101	3.1	8
16	Stage II and stage III colon cancer: treatment advances and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 202-9	2.2	35
15	Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 148-157	1	2
14	Echocardiographic follow-up of treated patients with carcinoid syndrome. <i>American Journal of Cardiology</i> , 2010 , 105, 1588-91	3	24
13	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. <i>International Journal of Cancer</i> , 2010 , 127, 1321-31	7.5	41
12	Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. <i>BMC Cancer</i> , 2009 , 9, 347	4.8	36
11	Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 605-12	3	4
10	Prognosis and predictive value of KIT exon 11 deletion in GISTs. <i>British Journal of Cancer</i> , 2009 , 101, 7-118.7		33

9	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5924-30	2.2	586
8	Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. <i>Gastroenterologie Clinique Et Biologique</i> , 2009 , 33, 1036-44		14
7	GIST with homozygous KIT exon 11 mutations. <i>Laboratory Investigation</i> , 2008 , 88, 456-7	5.9	11
6	KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , 2008 , 26, 374-9	2.2	1240
5	Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 255-62	7	58
4	Cetuximab efficacy in patients treated routinely in university hospitals. <i>Gastroenterologie Clinique Et Biologique</i> , 2007 , 31, 941-9		3
3	Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?. <i>Gastroenterologie Clinique Et Biologique</i> , 2007 , 31, 151-6		5
2	Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2007 , 46, 60-8	13.4	52
1	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. <i>Cancer Research</i> , 2006 , 66, 3992-5	10.1	1852